| PATENT REGISTER | |||||||||||||||||||
| A Supplementary Protection Certificate (SPC) exists for this Patent. To view the SPC Details click following SPC number(s): 2023/002 | |||||||||||||||||||
| Status | Granted | Patent No. | 3242887 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Application No. | 16703620.1 | Date of Filing | 05/01/2016 | ||||||||||||||||
| Date Grant Published | 14/08/2019 | Application Published | 15/11/2017 | ||||||||||||||||
| Title of Invention | GIP AND GLP-1 CO-AGONIST COMPOUNDS | ||||||||||||||||||
| Priority |
|
||||||||||||||||||
| Inventors |
ALSINA-FERNANDEZ, Jorge BOKVIST, Bengt Krister COSKUN, Tamer CUMMINS, Robert Chadwick |
||||||||||||||||||
| Current Proprietor |
Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 UNITED STATES OF AMERICA |
||||||||||||||||||
| Address for service |
FRKelly Waterways House Grand Canal Quay Dublin D02 PD39 IRELAND |
||||||||||||||||||
| Renewal Fees |
|
||||||||||||||||||
| Publication Language | English | ||||||||||||||||||
| Translation Received Date | |||||||||||||||||||
| 30/08/2019 | Address for Service recorded as FRKelly, 27 Clyde Road, Ballsbridge, Dublin 4, Ireland received on 29/08/2019. | ||||||||||||||||||
| 05/09/2019 | Divisional Application number: 19188718.1 Date of receipt: 26/07/2019 | ||||||||||||||||||
| 26/01/2023 | Request for grant a Supplementary Protection Certificate, citing Patent number 3242887 as the relevant basic patent, in respect of the product tirzepatide and pharmaceutically acceptable salts thereof filed on 25/01/2023. Reference number of request is 2023/002. | ||||||||||||||||||
